Good news doesn't travel to every corner. The overall market rose yet again, but shareholders of three health-care stocks are certainly not singing a happy tune after the past week.

One of the big losers could just be experiencing the effects of profit-taking after a huge stock run-up. Another felt the sting of an analyst report citing concerns about a clinical study in progress. Yet another absorbed the impact of announcing a big secondary offering that dilutes existing shareholders' stock value.

Which stocks were crushed badly by the market this week? Find out by watching the following slideshow.


Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.